L. Hansen Carl - 25 Nov 2024 Form 4 Insider Report for AbCellera Biologics Inc. (ABCL)

Role: Chief Executive Officer, Director, 10%+ Owner
Signature: Tryn Stimart, attorney-in-fact
Issuer symbol: ABCL
Transactions as of: 25 Nov 2024
Transactions value $: $151,538
Form type: 4
Filing time: 26 Nov 2024, 17:38:20 UTC
Previous filing: 24 Sep 2024
Next filing: 03 Jan 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABCL	Common Shares	Options Exercise	$152K	+56.1K	+6.67%	$2.70	898K	25 Nov 2024	Direct
holding	ABCL	Common Shares						56.1M	25 Nov 2024	See footnote	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABCL	Share option (right to buy)	Options Exercise	$0	-56.1K	-0.67%	$0.00	8.26M	25 Nov 2024	Common Shares	56.1K	$2.70	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares are held by Thermopylae Holdings Ltd., which is an entity wholly owned by the reporting person.
F2	The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on November 18, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date.